Supporting opportunities for enhanced competition in the marketplace

Promoting competition is an important focus for the biopharmaceutical industry. Since 1984, the Hatch-Waxman Act has fostered robust competition through the timely entry of generic medicines into the...
Read More
Opportunities to build upon enhanced competition for medicines in the marketplace

Last week, I presented at the U.S Food and Drug Administration’s (FDA) public meeting on the Hatch-Waxman Amendments to discuss the balance between encouraging innovation in biopharmaceutical...
Read More
What are REMS? These extra steps are helping protect patient health

As a physician and chief medical officer at PhRMA, I know how important it is to ensure that patients have access to safe, innovative medicines to help them live longer, healthier lives. But equally...
Read More